---
title: "Research Alert: CFRA Maintains Hold Opinion On Shares Of Alnylam Pharmaceuticals, Inc"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285062203.md"
description: "CFRA maintains a hold opinion on Alnylam Pharmaceuticals, lowering the target price to $319 from $340. They raised the 2026 EPS forecast to $9.32, while keeping the 2027 estimate at $11.97. Alnylam reported a strong Q1 2026, surpassing $1B in quarterly product revenue for the first time, driven by AMVUTTRA's launch. However, international TTR revenue grew 35% year-over-year but declined by $7 million from the previous quarter due to a price adjustment in Germany. The concentration of revenue in the TTR franchise poses potential risks."
datetime: "2026-05-04T10:55:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285062203.md)
  - [en](https://longbridge.com/en/news/285062203.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285062203.md)
---

# Research Alert: CFRA Maintains Hold Opinion On Shares Of Alnylam Pharmaceuticals, Inc

06:55 AM EDT, 05/04/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target price to $319 from $340 based on our NPV analysis. We raise our 2026 EPS forecast to $9.32 from $8.02, and maintain our 2027 EPS estimate at $11.97. Alnylam (ALNY) reported a strong first quarter for 2026, exceeding both earnings and revenue estimates. The company achieved a significant milestone, in our view, surpassing $1B in quarterly product revenue for the first time in its history. This performance was largely due to the successful commercial launch and uptake of AMVUTTRA for ATTR-CM. While international TTR revenue grew 35% year-over-year in Q1, it declined by $7 million from the previous quarter. This was mainly due to a previously announced price adjustment in Germany following the ATTR-CM launch. We think a significant portion of ALNY's revenue is concentrated in its TTR franchise, which could be a vulnerability if new competitors or unforeseen challenges emerge.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [TBXU.US](https://longbridge.com/en/quote/TBXU.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Thrivent Financial for Lutherans Buys New Stake in Alnylam Pharmaceuticals, Inc. $ALNY](https://longbridge.com/en/news/287050595.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)